Abbott Laboratories (ABT) Accumulated Expenses (2009 - 2026)

Abbott Laboratories' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 3.86% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 3.86% YoY), while the FY2025 annual figure was $1.7 billion, up 2.59% from the prior year.
• Accumulated Expenses came in at $1.2 billion for Q1 2026 at Abbott Laboratories, down from $1.7 billion in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.7 billion in Q4 2025 to a low of $1.1 billion in Q1 2024.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses declined 4.27% in 2023 and increased 11.59% in 2025, its largest moves.
• Abbott Laboratories' Accumulated Expenses stood at $1.6 billion in 2022, then climbed by 2.63% to $1.6 billion in 2023, then rose by 6.51% to $1.7 billion in 2024, then rose by 2.59% to $1.7 billion in 2025, then plunged by 30.54% to $1.2 billion in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.2 billion, $1.7 billion, and $1.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison